Abstract
Neoadjuvant ‘Full Dose’ oxaliplatin/capecitabine/radiotherapy for MRI selected ‘very’ high risk rectal cancers with gross circumferential resection margin (CRM) involvement
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
